FDA approves Viatris’ Ryzumvi for adult presbyopia
Viatris holds exclusive rights to commercialise phentolamine ophthalmic solution 0.75% across the US.
Drug Development
Estuary secures $103m to advance kidney disease gene therapies
Acta Pharmaceuticals raises $24m for Alzheimer’s therapies
Transcripta Bio, Mayo Clinic join force on ALS therapies
QCi and INmune Bio partner to study XPro in Alzheimer’s
Charles River partners with Magellan Stem Cells on cell therapy
Pfizer partners with Enodia Therapeutics in $500m drug deal
China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
